AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21811866 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 months
Number of subjects: 89
Study 20633818 — intervention group
Group type: EXPERIMENTAL
Intervention: SXscore<or=8 (SXlow) (n=464)
Number of subjects: 1397
Study 20633818 — intervention group
Group type: EXPERIMENTAL
Intervention: SXscore>8 and <or=16 (SXmid) (n=472)
Number of subjects: 1397
Study 20633818 — intervention group
Group type: EXPERIMENTAL
Intervention: SXscore>16 (SXhigh) (n=461)
Number of subjects: 1397
Study 20633818 — intervention group
Group type: COMPARATOR
Intervention: SXscore<or=8 (SXlow)
Number of subjects: 1397
Study 20633818 — intervention group
Group type: COMPARATOR
Intervention: SXscore>8 and <or=16 (SXmid)
Number of subjects: 1397
Study 20633818 — intervention group
Group type: COMPARATOR
Intervention: SXscore>16 (SXhigh)
Number of subjects: 1397
Study 16911813 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 89
Study 16911813 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg/day
Number of subjects: 89
Study 16911813 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Orlistat and Fenofibrate
Number of subjects: 89
Study 16911813 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 89
Study 15951101 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol every 4 h
Number of subjects: 99
Study 15951101 — intervention group
Group type: COMPARATOR
Intervention: 50 microg vaginal misoprostol every 4 h
Number of subjects: 99
Study 12030962 — intervention group
Group type: EXPERIMENTAL
Intervention: Alverine citrate (120 mg capsule, three times daily for 12 weeks)
Number of subjects: 107
Study 12030962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 12030962 — intervention group
Group type: EXPERIMENTAL
Intervention: Alverine citrate
Number of subjects: 107
Study 10081543 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 20
Study 10081543 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask insertion
Number of subjects: 20
Study 7741779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine-ratiopharm mite (200 mg)
Number of subjects: 0
Study 7741779 — intervention group
Group type: COMPARATOR
Intervention: Commercial reference preparation
Number of subjects: 0
Study 7741779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 0
Study 1791021 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidi smokers
Number of subjects: 125
Study 1791021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 125
Study 1791021 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed smokers
Number of subjects: 125
Study 1791021 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic cigarette smokers
Number of subjects: 125
Study 1791021 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-smokers (control)
Number of subjects: 125
Study 1791021 — intervention group
Group type: EXPERIMENTAL
Intervention: All smokers
Number of subjects: 125
Study 7050907 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 10
Study 7050907 — intervention group
Group type: COMPARATOR
Intervention: Regional heparinisation
Number of subjects: 10
Study 31779479 — intervention group
Group type: EXPERIMENTAL
Intervention: At-Home urine collection methodology
Number of subjects: 0
Study 30566590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus SOX
Number of subjects: 40
Study 30566590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus CapeOX
Number of subjects: 40
Study 25892165 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led training (ILT)
Number of subjects: 172
Study 25892165 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training (OLT)
Number of subjects: 172
Study 25892165 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment manual (TM)
Number of subjects: 172
Study 25892165 — intervention group
Group type: COMPARATOR
Intervention: All conditions (ILT, OLT, TM)
Number of subjects: 172
Study 23795737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (125 mg bid)
Number of subjects: 28
Study 23795737 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingko biloba (120 mg bid)
Number of subjects: 28
Study 23795737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20153154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 200mg red yeast rice extract and 10mg policosanols once-daily for 8 weeks
Number of subjects: 40
Study 20153154 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 40
Study 19624076 — intervention group
Group type: EXPERIMENTAL
Intervention: Viabahn polytetrafluoroethylene-covered stent-grafts
Number of subjects: 0
Study 19624076 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding bare nitinol stents
Number of subjects: 0
Study 19624076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 0
Study 19624076 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent without a polymer coating
Number of subjects: 0
Study 19624076 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 0
Study 19624076 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloons coated with paclitaxel
Number of subjects: 0
Study 17704425 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT‐IA (150 mg/m², four courses) with sodium thiosulfate
Number of subjects: 158
Study 17704425 — intervention group
Group type: COMPARATOR
Intervention: CRT‐IV (100 mg/m², three courses) without sodium thiosulfate
Number of subjects: 158
Study 15073851 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and Paclitaxel (CP) - Paclitaxel at a dose of 225 mg/m² and carboplatin (AUC of 6) every 21 days
Number of subjects: 85
Study 15073851 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) - standard dosage
Number of subjects: 85
Study 15073851 — intervention group
Group type: COMPARATOR
Intervention: Comparison of toxicities
Number of subjects: 85
Study 15073851 — intervention group
Group type: COMPARATOR
Intervention: Quality of life assessment using FACT-BL
Number of subjects: 85
Study 11560562 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (ABC) with ASA
Number of subjects: 18
Study 11560562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (T) with ASA
Number of subjects: 18
Study 11560562 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) with ABC and ASA
Number of subjects: 18
Study 11560562 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) with T and ASA
Number of subjects: 18
Study 11560562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (reviparin, REV) with ABC and ASA
Number of subjects: 18
Study 11560562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (reviparin, REV) with T and ASA
Number of subjects: 18
Study 11560562 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ABC and ASA
Number of subjects: 18
Study 11560562 — intervention group
Group type: COMPARATOR
Intervention: Placebo with T and ASA
Number of subjects: 18
Study 9460232 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 160 micrograms/m3 for 60 min
Number of subjects: 9
Study 9460232 — intervention group
Group type: COMPARATOR
Intervention: Exposure to 40 micrograms/m3 for 60 min
Number of subjects: 9
Study 8179144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation
Number of subjects: 100
Study 8179144 — intervention group
Group type: COMPARATOR
Intervention: Rigid laryngoscopic intubation
Number of subjects: 100
Study 8179144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 3259002 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 12
Study 3259002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 12
Study 3259002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3259002 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12
Study 31710593 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage (15-min twice a day for 3 days)
Number of subjects: 70
Study 31710593 — intervention group
Group type: COMPARATOR
Intervention: Routine cares (control group)
Number of subjects: 70
Study 30987668 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and DHA supplementation (600 mg EPA and 260 mg DHA per day for 8 weeks)
Number of subjects: 16
Study 30987668 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 16
Study 28389552 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg TCZ + MTX
Number of subjects: 1157
Study 28389552 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 1157
Study 28389552 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/kg TCZ + MTX
Number of subjects: 1157
Study 25644503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 24
Study 25644503 — intervention group
Group type: COMPARATOR
Intervention: Blank Control
Number of subjects: 24
Study 23606811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position group
Number of subjects: 120
Study 23606811 — intervention group
Group type: COMPARATOR
Intervention: Supine position group
Number of subjects: 120
Study 21423068 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of panretinal photocoagulation using pattern scan laser
Number of subjects: 50
Study 21423068 — intervention group
Group type: COMPARATOR
Intervention: Multiple sessions of conventional laser
Number of subjects: 50
Study 19785727 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive for each anti-psychotic depot medication received over a 12 month period
Number of subjects: 136
Study 19785727 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 136
Study 17010227 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with nucleotides (NT+; n 13)
Number of subjects: 26
Study 17010227 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula without nucleotides (NT-; n 13)
Number of subjects: 26
Study 17010227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional recovery
Number of subjects: 26
Study 17010227 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and nutritional recovery
Number of subjects: 26
Study 17010227 — intervention group
Group type: EXPERIMENTAL
Intervention: All variables included
Number of subjects: 26
Study 15554359 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic peptide corresponding to residues 34-39 in TSHR
Number of subjects: 0
Study 15554359 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiserum to the synthetic peptide corresponding to residues 34-39 in TSHR
Number of subjects: 0
Study 15554359 — intervention group
Group type: COMPARATOR
Intervention: Alphal-antitrypsin
Number of subjects: 0
Study 11499801 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 41
Study 11499801 — intervention group
Group type: COMPARATOR
Intervention: Inhibitor titer < 2.0 U/mL
Number of subjects: 41
Study 11499801 — intervention group
Group type: COMPARATOR
Intervention: Inhibitor titer >= 2.0 U/mL
Number of subjects: 41
Study 11499801 — intervention group
Group type: COMPARATOR
Intervention: Neurological abnormalities
Number of subjects: 41
Study 9230853 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 50
Study 9230853 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 50
Study 8501085 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a tourniquet (Group 1)
Number of subjects: 80
Study 8501085 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet (Group 2)
Number of subjects: 80
Study 3656551 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone catheters
Number of subjects: 0
Study 3656551 — intervention group
Group type: COMPARATOR
Intervention: Teflon-coated catheters
Number of subjects: 0
Study 3656551 — intervention group
Group type: COMPARATOR
Intervention: Latex catheters
Number of subjects: 0
Study 3656551 — intervention group
Group type: COMPARATOR
Intervention: Silicone-coated catheters
Number of subjects: 0
Study 31542384 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoketoconazole, starting at 150 mg twice daily, titrated up to a maximum of 600 mg twice daily during a 2-21 week dose-titration phase followed by a 6-month maintenance phase.
Number of subjects: 94
Study 31542384 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoketoconazole treatment
Number of subjects: 94
Study 27506909 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive habitual expectations
Number of subjects: 76
Study 27506909 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated expectations (multimedia presentations suggesting different health benefits)
Number of subjects: 76
Study 27506909 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (moderate 30 min cycling)
Number of subjects: 76
Study 26464000 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of dexmedetomidine (DEX) 0.8 μg · kg‐1 · min‐1
Number of subjects: 40
Study 26464000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study 24888284 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 30
Study 24888284 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study 22760426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine
Number of subjects: 86
Study 22760426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 19388120 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium doped saline flush (50 mM gadolinium, total Gd: 0.11 mmol/kg, flow-rate: 2 mL/s)
Number of subjects: 22
Study 19388120 — intervention group
Group type: COMPARATOR
Intervention: Pure saline flush (0.9% saline solution)
Number of subjects: 22
Study 18086963 — intervention group
Group type: EXPERIMENTAL
Intervention: TORS radical tonsillectomy
Number of subjects: 27
Study 14983408 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + recombinant human growth hormone (rhGH) (daily dose 9.5 microg/kg body weight)
Number of subjects: 25
Study 14983408 — intervention group
Group type: COMPARATOR
Intervention: Metformin + Placebo
Number of subjects: 25
Study 12483466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day for 6 months
Number of subjects: 43
Study 12483466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10450619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) led by professional therapists
Number of subjects: 98
Study 10450619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) led by paraprofessional therapists
Number of subjects: 98
Study 10450619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual Support Group Therapy (MSG) led by professional therapists
Number of subjects: 98
Study 10450619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual Support Group Therapy (MSG) led by paraprofessional therapists
Number of subjects: 98
Study 10450619 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 98
Study 7570730 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (1 g/kg body wt)
Number of subjects: 17
Study 7570730 — intervention group
Group type: COMPARATOR
Intervention: Oral xylose (0.83 g/kg)
Number of subjects: 17
Study 7570730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt (60 degrees)
Number of subjects: 17
Study 2695156 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical lignocaine
Number of subjects: 70
Study 2695156 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 70
Study 732296 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 pollen extract capsules
Number of subjects: 18
Study 732296 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 protein extract capsules
Number of subjects: 18
Study 732296 — intervention group
Group type: COMPARATOR
Intervention: 4 placebo capsules
Number of subjects: 18
Study 30898111 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy (28 sessions)
Number of subjects: 8
Study 28895143 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasonography (LUS)
Number of subjects: 300
Study 28895143 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy alone (Control)
Number of subjects: 300
Study 25697911 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional retraining
Number of subjects: 118
Study 25697911 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 118
Study 24821974 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspaper articles (9 groups assigned to different articles)
Number of subjects: 1950
Study 24821974 — intervention group
Group type: COMPARATOR
Intervention: Excerpt of the official Association of Clinical Cancer Centers web pages (1 group)
Number of subjects: 1950
Study 24821974 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 1950
Study 22027860 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week medicine ball training program
Number of subjects: 21
Study 22027860 — intervention group
Group type: COMPARATOR
Intervention: Regular training
Number of subjects: 21
Study 19679041 — intervention group
Group type: EXPERIMENTAL
Intervention: Invited to mammographic screening
Number of subjects: 2478
Study 19679041 — intervention group
Group type: COMPARATOR
Intervention: Not invited to mammography (Control)
Number of subjects: 2478
Study 19679041 — intervention group
Group type: COMPARATOR
Intervention: Diagnosed before the onset of the screening trial (Control)
Number of subjects: 2478
Study 17267098 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel SVI nomogram
Number of subjects: 666
Study 17267098 — intervention group
Group type: COMPARATOR
Intervention: Partin's SVI predictions
Number of subjects: 666
Study 17267098 — intervention group
Group type: COMPARATOR
Intervention: Koh's SVI nomogram
Number of subjects: 666
Study 17267098 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel SVI nomogram cutoff of 3% or less
Number of subjects: 666
Study 17267098 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect classification of patients
Number of subjects: 666
Study 14739689 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal presentation of sexually relevant CS (abdomen of the opposite sex)
Number of subjects: 56
Study 14739689 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious presentation of sexually relevant CS (abdomen of the opposite sex)
Number of subjects: 56
Study 14739689 — intervention group
Group type: COMPARATOR
Intervention: Control group with unpaired presentations of CS+ (abdomen), CS- (gun), and US (erotic film clip)
Number of subjects: 56
Study 14739689 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal presentation of sexually irrelevant CS (gun)
Number of subjects: 56
Study 14739689 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious presentation of sexually irrelevant CS (gun)
Number of subjects: 56
Study 11309322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of TNF with 1.5 mg/kg melphalan
Number of subjects: 32
Study 11309322 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg melphalan alone
Number of subjects: 32
Study 9550658 — intervention group
Group type: EXPERIMENTAL
Intervention: PermCath
Number of subjects: 286
Study 9550658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesio
Number of subjects: 286
Study 9550658 — intervention group
Group type: EXPERIMENTAL
Intervention: VasCath
Number of subjects: 286
Study 9550658 — intervention group
Group type: COMPARATOR
Intervention: AV access
Number of subjects: 286
Study 8116712 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography with revealed results
Number of subjects: 2986
Study 8116712 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasonography with concealed results
Number of subjects: 2986
Study 2787498 — intervention group
Group type: COMPARATOR
Intervention: Vestibular program (Control Group I)
Number of subjects: 30
Study 2787498 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercises (Experimental Group II)
Number of subjects: 30
Study 2787498 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular program (Experimental Group III)
Number of subjects: 30
Study 1259120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine administered 5 minutes before surgery to half of the patients (25 patients).
Number of subjects: 50
Study 1259120 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ketamine without atropine (unatropinised group, 25 patients).
Number of subjects: 50
Study 31252353 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy training intervention
Number of subjects: 116
Study 31252353 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 116
Study 28645853 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation group
Number of subjects: 19
Study 28645853 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation group
Number of subjects: 19
Study 26525622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopantenic acid (pantogam)
Number of subjects: 63
Study 26525622 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pantogam)
Number of subjects: 63
Study 23408342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-subvastus (SV) surgical approach
Number of subjects: 53
Study 23408342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-midvastus (MV) surgical approach
Number of subjects: 53
Study 23408342 — intervention group
Group type: COMPARATOR
Intervention: Both MV and SV surgical approaches
Number of subjects: 53
Study 22057076 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg intravenous, starting from the 3rd week of transplantation for 3 months)
Number of subjects: 40
Study 22057076 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg oral per week for 3 months)
Number of subjects: 40